Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “buy” rating reaffirmed by Cowen in a research report issued on Tuesday, AnalystRatings.com reports.
A number of other equities analysts have also recently commented on AGIO. Cantor Fitzgerald assumed coverage on shares of Agios Pharmaceuticals in a report on Tuesday, November 26th. They issued an “overweight” rating and a $64.00 target price on the stock. Citigroup lowered their price objective on shares of Agios Pharmaceuticals from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Zacks Investment Research lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating and set a $40.00 price objective on the stock. in a research report on Monday, September 16th. Royal Bank of Canada set a $79.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Guggenheim upgraded shares of Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $63.18.
Shares of Agios Pharmaceuticals stock traded up $0.90 during trading on Tuesday, reaching $51.31. The company’s stock had a trading volume of 11,971 shares, compared to its average volume of 630,389. The company has a 50-day moving average price of $45.82 and a two-hundred day moving average price of $40.51. The firm has a market cap of $2.90 billion, a PE ratio of -8.50 and a beta of 2.35. Agios Pharmaceuticals has a fifty-two week low of $28.36 and a fifty-two week high of $68.94. The company has a current ratio of 5.30, a quick ratio of 5.24 and a debt-to-equity ratio of 0.24.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.85) by $0.04. The business had revenue of $26.02 million for the quarter, compared to analysts’ expectations of $33.13 million. Agios Pharmaceuticals had a negative net margin of 356.42% and a negative return on equity of 70.07%. The company’s quarterly revenue was up 71.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.63) EPS. On average, analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.
In other Agios Pharmaceuticals news, CEO Jacqualyn A. Fouse acquired 40,322 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were acquired at an average cost of $31.00 per share, for a total transaction of $1,249,982.00. Following the transaction, the chief executive officer now directly owns 41,722 shares of the company’s stock, valued at $1,293,382. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Corp /De/ Celgene acquired 403,225 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $31.00 per share, for a total transaction of $12,499,975.00. Following the completion of the transaction, the insider now directly owns 1,777,824 shares in the company, valued at $55,112,544. The disclosure for this purchase can be found here. Insiders have acquired a total of 451,611 shares of company stock worth $13,999,941 over the last 90 days. Insiders own 3.16% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AGIO. NumerixS Investment Technologies Inc purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $35,000. Steward Partners Investment Advisory LLC raised its stake in Agios Pharmaceuticals by 430.6% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 1,109 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 900 shares during the last quarter. First Mercantile Trust Co. acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at about $44,000. US Bancorp DE raised its stake in Agios Pharmaceuticals by 82.6% in the 2nd quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 457 shares during the last quarter. Finally, ETF Managers Group LLC raised its stake in Agios Pharmaceuticals by 63.0% in the 2nd quarter. ETF Managers Group LLC now owns 2,851 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 1,102 shares during the last quarter.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Recommended Story: Stocks at 52 Week High
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.